Posters

Aflibercept in treatment-naive patients with diabetic macular edema in a real-life setting

Poster Details

First Author: M.Nghiem-Buffet FRANCE

Co Author(s):    A. Giocanti-Auregan   L. Qu-Knafo   L. Hrarat   T. Grenet   B. Bodaghi   F. Fajnkuchen              

Abstract Details



Purpose:

Diabetic macular edema (DME) is the leading cause of blindness in diabetic patients. Pivotal studies have demonstrated the efficacy of aflibercept intravitreal injections (IVI) on DME. The aim of this study was to assess the efficacy and safety of aflibercept in treatment-naive DME patients in a real-life setting.

Setting:

A retrospective, bi-centre study conducted in 2 tertiary centres specialized in imaging and treatment of retinal diseases.

Methods:

A retrospective, bi-centre study was conducted in all consecutive treatment-naive patients diagnosed with DME treated with 5 monthly injections of aflibercept followed by bimonthly IVI. Primary endpoint was the mean change in best-corrected visual acuity (BCVA) between baseline and month 6 of follow-up (M6).

Results:

Twenty-five eyes of 21 patients were included. BCVA improved from 61±11.7 letters at baseline to 70.3±8.4 letters at M6 (mean IVI number: 4.96; mean variation: +9.3 letters). At M6, 24% and 32% of eyes gained more than 15 and 10 letters, respectively and 72% reached the threshold of 70 letters. The mean central retinal thickness decreased from 392±61 µm at baseline to 286±59 µm at M6 (mean variation: –106 µm). At M6, the edema was completely resolved with a flat retina in 56% of eyes.

Conclusions:

At M6, aflibercept significantly improved functional and anatomical outcomes in treatment-naive DME patients in a real-life setting.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy